Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
Budman DR, Johnson R, Barile B, Bowsher RR, Vinciguerra V, Allen SL, Kolitz J, Ernest CS 2nd, Kreis W, Zervos P, Walling J.
Budman DR, et al. Among authors: bowsher rr.
Cancer Chemother Pharmacol. 2001 Jun;47(6):525-31. doi: 10.1007/s002800000272.
Cancer Chemother Pharmacol. 2001.
PMID: 11459206
Clinical Trial.